Target
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
Background
Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody.• Cancer immunotherapy using checkpoint blockade., PMID:29567705• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870• Immune-related adverse events of checkpoint inhibitors., PMID:32382051• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845• Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885• Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160• Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858• Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704